Imperial College London
Portrait Picture

ProfessorDannyAltmann

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immunology
 
 
 
//

Contact

 

+44 (0)20 3313 8212d.altmann

 
 
//

Location

 

5S5CHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pinato:2019:10.1186/s40425-019-0775-x,
author = {Pinato, DJ and Gramenitskaya, D and Altmann, DM and Boyton, RJ and Mullish, BH and Marchesi, JR and Bower, M},
doi = {10.1186/s40425-019-0775-x},
journal = {Journal for ImmunoTherapy of Cancer},
title = {Antibiotic therapy and outcome from immune-checkpoint inhibitors},
url = {http://dx.doi.org/10.1186/s40425-019-0775-x},
volume = {7},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic mechanisms underlying the association with outcome are poorly understood. Perturbation of the gut microbiota, an increasingly well-characterized factor capable of influencing ICPI-mediated immune reconstitution, has been indicated as a putative mechanism to explain the adverse effects attributed to antibiotic exposure in the context of ICPI therapy. Prospective studies are required to validate antibiotic-mediated gut perturbations as a mechanism of ICPI refractoriness and guide the development of strategies to overcome this barrier to an effective delivery of anti-cancer immunotherapy.
AU  - Pinato,DJ
AU  - Gramenitskaya,D
AU  - Altmann,DM
AU  - Boyton,RJ
AU  - Mullish,BH
AU  - Marchesi,JR
AU  - Bower,M
DO  - 10.1186/s40425-019-0775-x
PY  - 2019///
SN  - 2051-1426
TI  - Antibiotic therapy and outcome from immune-checkpoint inhibitors
T2  - Journal for ImmunoTherapy of Cancer
UR  - http://dx.doi.org/10.1186/s40425-019-0775-x
UR  - http://hdl.handle.net/10044/1/73861
VL  - 7
ER  -
Download